Raymond James analyst Jayson Bedford reiterated a Strong Buy rating and $121.00 price target on Boston Scientific (NYSE: BSX)

The analyst comments "We expect the discontinuation of Acurate will take away a small portion of the upside, and will add noise to the 2Q print/’25 guide, but this should be factored into sentiment, even if it is not fully factored into estimates. With this note, we remove Acurate and highlight the various offsets. We expect 2Q upside, driven largely by Electrophysiology (EP) and Watchman (WM), but also believe there should be upside from the rest of the portfolio in 2H. BSX remains one of the top two (along with ISRG) fastest growing companies in MedTech, and we expect this dynamic to continue through 2026. Teens revenue growth with visible operating leverage justifies a premium multiple, and supports our Strong Buy rating."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $103.64 yesterday.